Fortress Biotech, Inc. (FBIOP) Gross Margin (2015 - 2026)
Fortress Biotech (FBIOP) posted quarterly Gross Margin of 61.3% for Q4 2025, down 783.0% year-over-year from 8.97% in Q4 2024, and down 9.0% quarter-over-quarter from 67.36% in Q3 2025.
Fortress Biotech, Inc. (FBIOP) Gross Margin (2015 - 2026) Analysis & Trends
Fortress Biotech's Gross Margin history runs 11 years deep, the most recent figure standing at 61.3% for Q4 2025.
- In Q4 2025, Gross Margin fell 783.0% year-over-year to 61.3%; the TTM figure through Dec 2025 stood at 65.03% (up 121.0% YoY), while the FY2025 annual figure was 65.83%, up 203.0% from the prior year.
- Gross Margin for Q4 2025 stood at 61.3%, down from 67.36% in the prior quarter.
- The five-year high for Gross Margin was 113.43% in Q4 2022, with the low at 4728.39% in Q2 2021.
- The 5-year median for Gross Margin is 59.72% (2022), against an average of 747.75%.
- The sharpest annual moves came in 2021 and 2022: Gross Margin tumbled 479535 bps in 2021, then surged 478653 bps in 2022.
- Fortress Biotech's Gross Margin stood at 83.71% in 2021, then soared by 35 bps to 113.43% in 2022, then dropped by 25 bps to 85.27% in 2023, then decreased by 19 bps to 69.13% in 2024, then slipped by 11 bps to 61.3% in 2025.
- Business Quant data shows FBIOP's Gross Margin at 61.3% in Q4 2025, 67.36% in Q3 2025, and 67.09% in Q2 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 67.18% |
| Dec 31, 2025 | 61.30% |
| Sep 30, 2025 | 67.36% |
| Jun 30, 2025 | 67.09% |
| Mar 31, 2025 | 63.54% |
| Dec 31, 2024 | 69.13% |
| Sep 30, 2024 | 69.44% |
| Jun 30, 2024 | 61.55% |
| Mar 31, 2024 | 53.94% |
| Dec 31, 2023 | 85.27% |
| Sep 30, 2023 | -3,432.42% |
| Jun 30, 2023 | -4,144.26% |
| Mar 31, 2023 | 46.99% |
| Dec 31, 2022 | 113.43% |
| Sep 30, 2022 | -1,883.79% |
| Jun 30, 2022 | 58.14% |
| Mar 31, 2022 | -1,321.66% |
| Dec 31, 2021 | 83.71% |
| Sep 30, 2021 | 43.05% |
| Jun 30, 2021 | -4,728.39% |